Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, April 19, 2014
Technology Networks
 
Register | Sign in
Home Page
  News
Return

ATLAS Biolabs is Awarded Certified Service Provider Accreditation from Affymetrix for DMET Analysis

Published: Tuesday, September 25, 2012
Last Updated: Tuesday, September 25, 2012
Bookmark and Share
DMET Plus uses microarray testing to investigate common variations in genes encoding for drug-metabolism enzymes and drug transporters, and to identify their impact on the individual metabolic capacity.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Domainex Programme Shows Great Promise for the Treatment of Inflammatory Diseases
Company’s IKKe/TBK1 programme to offer a disease-modifying treatment for COPD patients.
Drug Does Not Improve Set of Cardiovascular Outcomes for Diastolic Heart Failure
NIH-supported study finds drug does appear to reduce hospitalizations for diastolic heart failure.
Blocking DNA Repair Mechanisms Could Improve Brain Cancer Therapy
The findings were published April 7 in Nature Communications.
Aspirin Does Not Prevent Pregnancy Loss, NIH Study Finds
Increased live birth rate in subgroup of participants.
Statins Slow the Progression of Advanced MS in Clinical Trial
The work is published in the Lancet.
Researchers Discover Underlying Genetics, Marker for Stroke, Cardiovascular Disease
NIH-funded findings point to new potential strategies for disease prevention, treatment.
New Clinical Study on the Relationship Between Imaging and OVA1®
New analysis explores interactions between clinical risk factors used in pre-surgical assessment.
Statins Slow the Progression of Advanced MS in Clinical Trial
The work is published in the Lancet.
Sepsis Study Comparing Three Treatment Methods Shows Same Survival Rate
NIH-funded clinical trial tested specific protocols against usual high-level care.
New Trial of Personalized Cancer Treatment Begins in Oxford
Phase I trial in Oxford will investigate a new drug, called CXD101.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv